Neurocrine Biosciences Inc (NBIX) — Cash Flow Quality Index
Neurocrine Biosciences Inc (NBIX) has a Cash Flow Quality Index of 2.53x as of December 2025. Operating cash flow of $388.40 Million exceeds net income of $153.70 Million, indicating high earnings quality where cash backs reported profits. Explore NBIX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Neurocrine Biosciences Inc Cash Flow Quality Index (1996–2025)
Historical Cash Flow Quality Index for Neurocrine Biosciences Inc across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Neurocrine Biosciences Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Neurocrine Biosciences Inc (1996–2025)
Year-by-year earnings quality comparison for Neurocrine Biosciences Inc. For live market cap and the full company financial profile, see Neurocrine Biosciences Inc market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.64x | $782.70 Million | $478.60 Million | ▼ -6.3% |
| 2024 | 1.74x | $595.40 Million | $341.30 Million | ▲ +11.7% |
| 2023 | 1.56x | $389.90 Million | $249.70 Million | ▼ -28.9% |
| 2022 | 2.20x | $339.40 Million | $154.50 Million | ▼ -23.3% |
| 2021 | 2.86x | $256.50 Million | $89.60 Million | ▲ +410.3% |
| 2020 | 0.56x | $228.50 Million | $407.30 Million | ▼ -85.9% |
| 2019 | 3.97x | $147.00 Million | $37.00 Million | ▼ -17.3% |
| 2018 | 4.81x | $101.40 Million | $21.10 Million | ▲ +168.4% |
| 2012 | -7.02x | $-35.29 Million | $5.03 Million | ▼ -37706.1% |
| 2011 | -0.02x | $-698.00K | $37.57 Million | ▼ -100.9% |
| 1997 | 2.16x | $11.00 Million | $5.10 Million | ▲ +89.9% |
| 1996 | 1.14x | $6.70 Million | $5.90 Million | — |